Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?

The anti-CD52 (Campath-1) monoclonal antibodies (Mabs) have a substantial history of use for controlling graft-versus-host disease in allogeneic bone marrow transplantation. Now, with the availability of a humanised form, alemtuzumab (Campath-1H), and the demonstration that this agent can reduce the...

תיאור מלא

מידע ביבליוגרפי
Main Authors: Hale, G, Slavin, S, Goldman, J, Mackinnon, S, Giralt, S, Waldmann, H
פורמט: Journal article
שפה:English
יצא לאור: 2002

פריטים דומים